Related Experiment Videos
[A study of crystallization on urolithiasis in vitro]
K Miyazawa1, K Suzuki, R Tsugawa
1Department of Urology, Kanazawa Medical University.
Hinyokika Kiyo. Acta Urologica Japonica
|October 1, 1991
Summary
CG-120 and sodium pentosan polysulfate (SPP) inhibit calcium oxalate crystal formation, growth, and aggregation. These compounds show potential for preventing kidney stones by reducing crystal development in various experimental systems.
Area of Science:
- Nephrology
- Crystallography
- Pharmacology
Context:
- Calcium oxalate crystals are the most common cause of kidney stones.
- Understanding crystal formation and growth is crucial for developing treatments.
- Existing treatments have limitations, necessitating novel therapeutic approaches.
Purpose:
- To evaluate the inhibitory effects of CG-120 and sodium pentosan polysulfate (SPP) on calcium oxalate crystal formation, growth, and aggregation.
- To investigate the impact of these compounds on nucleation rates and crystal deposition in vivo.
- To develop and utilize a new system for observing crystal formation and growth post-extracorporeal shock wave lithotripsy.
Summary:
- A Coulter counter was used to assess calcium oxalate crystal formation, growth, and aggregation.
- Both CG-120 and SPP demonstrated inhibitory activity in seeded and whole urine systems.
- In a continuous crystallizer, these agents reduced the nucleation rate. A novel system observed fragmented stone growth post-lithotripsy, with CG-120 inhibiting this growth.
- In vivo studies in rats showed SPP inhibited calcium oxalate crystal growth in the kidney.
Impact:
- CG-120 and SPP show promise as therapeutic agents for preventing or treating calcium oxalate kidney stones.
- The findings contribute to the understanding of anti-urolithic mechanisms.
- This research may lead to new strategies for managing nephrolithiasis.